Dr Lal PathLabs to acquire 70% stake in genomics firm SN Genelab for up to ₹168 crore
Dr Lal PathLabs to acquire 70% stake in SN Genelab for up to ₹168 crore.
Acquisition to be funded through cash consideration and completed by November 30, 2026.
SN Gene operates in diagnostics-genomics industry, providing genomics diagnostic services with ₹57.96 crore turnover in FY26.
Dr Lal PathLabs aims to strengthen expertise in genomics and broaden diagnostic services portfolio.